Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pivotal phase III trial of pimavanserin in patients with Parkinson's disease-related psychosis (ACP-103-021).

Trial Profile

Pivotal phase III trial of pimavanserin in patients with Parkinson's disease-related psychosis (ACP-103-021).

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Parkinson's disease; Psychotic disorders
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 11 Apr 2013 ACADIA will no longer conduct this trial following an FDA announcement indicating data from the 020 trial, in conjunction with earlier phase trials, was sufficient to support regulatory filing activities.
    • 11 Apr 2013 Status changed from planning to discontinued based on information reported in an ACADIA Pharmaceuticals media release.
    • 29 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top